1253P - A prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with radiotherapy for non-small-cell lung cancer pati...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Surgical Oncology
Non-Small Cell Lung Cancer
Radiation Oncology
Presenter Leiming Guo
Citation Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383
Authors L. Guo1, G.F. Ding2
  • 1Department Of Radiotherapy, Henan Provincial Anti-Cancer Hospital, 450000 - Zhengzhou/CN
  • 2Department Of Radiotherapy, Henan Provincial Anti-Cancer Hospital, Zhengzhou/CN



To establish the safety profile and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) concurrent with radiotherapy (RT) in patients with non–small-cell lung cancer (NSCLC) who have only bone oligometastases (1-3 lesions) progression after EGFR-TKIs therapy.


Between June 2012 and January 2015, 28 patients with Stage IV NSCLC were enrolled in this prospective study. They were treated with EGFR-TKIs (gefitinib 250mg or erlotinib 150 mg, oral daily), and concurrent with bone metastasis RT with curative intent when these patients had only bone oligometastases (1-3 lesions) progression. The RT plans were individually designed on the basis of tumor size and normal tissue volume constraints. The RT plans have two styles: 30Gy/10f. All patients were available for assessment of toxicity and efficacy. The primary endpoints were acute toxicity and overall survival. The secondary endpoints included median survival time and progression-free survival (PFS).


All patients completed the treatment protocol. Acute skin, hematologic, esophageal, gastrointestinal and systemic toxicities were mild. No serious adverse reaction was noted. With a median follow-up of 21.5 months, the local control rate of 92.8% was achieved for the bone metastases lesions. Median PFS, and median survival time were 16.2, and 21.5 months, respectively. The 1- and 2-year PFS rates were 69.8% and 26.2%, and 1-, 2-, and 3-year overall survival rates were 77.9%, 46.8%, and 23.4%, respectively.


For advanced NSCLC patients effectively treated with EGFR-TKIs, concurrent with individualized bone metastases lesions RT shows a favorable safety profile and promising outcome, therefore can serve as a therapeutic option for advanced NSCLC patients with only bone oligometastases progression.

Clinical trial identification

Legal entity responsible for the study

Henan Province Anti-cancer Hospital


Henan Province Anti-cancer Hospital


All authors have declared no conflicts of interest.